Uptake of Respiratory Syncytial Virus Protection in the Inaugural Prenatal Vaccination Season: A Tertiary Referral Center Experience [ID 847]

INTRODUCTION: Novel seasonal vaccination for respiratory syncytial virus (RSV) became available and was recommended to pregnant people between 32 0/7 and 36 6/7 weeks of gestation in 2023. Parents may alternatively elect neonatal monoclonal antibody treatment. We sought to evaluate trends in RSV protection uptake in the setting of targeted patient education campaigns. METHODS: This was a retrospective cohort study of pregnant people receiving care at a tertiary referral center who delivered between October 1, 2023, and March 31, 2024. The primary outcome was receipt of either parental vaccination or neonatal antibody treatment. The associations between RSV protection and demographics and receipt of other vaccinations in pregnancy were determined via Pearson’s chi-squared, Fisher’s exact, and Welch’s t-test. RESULTS: One thousand fifty-nine pregnant people were included, of which 68.5% (n=725) received RSV protection. Preterm birth (less than 37 weeks) was lower in those who received RSV vaccination (9.9% versus 17.8%, P <.001). People with lower uptake of RSV protection were more likely to have Medicaid insurance (63.6% versus 71.3% commercial, P =.037) or decline other prenatal vaccinations (Tdap: 26.1 versus 73.9% received; COVID-19: 15.4 versus 85.0% received; influenza: 21.5 versus 78.5 received; all P <.001). CONCLUSIONS/IMPLICATIONS: In the inaugural season of prenatal RSV vaccination, receipt of other routine prenatal vaccinations and commercial insurance support were associated with receipt of RSV protection. These data will inform ongoing system-wide quality improvement initiatives.